CUV9900

CUV9900 is a preclinical-stage topical small molecule developed by Clinuvel Pharmaceuticals. It is a melanocortin receptor-directed product designed for the treatment of various skin conditions. By targeting melanocortin receptors in the skin, CUV9900 aims to stimulate physiological processes such as melanogenesis and DNA repair, providing photoprotection and therapeutic benefits for dermatological disorders. Unlike Clinuvel's lead product afamelanotide, which is a peptide administered via implant, CUV9900 is formulated for topical application, allowing for localized delivery to the skin. The drug is currently being evaluated in preclinical studies to establish its safety and efficacy profile for future clinical development.